Modified VP1-capsid protein of parvovirus B19
OwnerSusanne Modrow, Torsten Lowin +2inventors
InventorsSusanne Modrow, Torsten Lowin, Markus Mobs, Michael Broker
Life of this patent
Estimating the term…
Abstract
The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.
Claims16
A pharmaceutical composition comprising a modified VP1-capsid protein of parvovirus B19, wherein a wild type sequence of the VP-1 capsid protein has been modified to contain amino acid substitutions at positions corresponding to histidine 153 of SEQ ID NO:1, tyrosine 157 of SEQ ID NO:1, lysine 162 of SEQ ID NO:1, and tyrosine 168 of SEQ ID NO:1, wherein said substitutions are histidine 153 to alanine, tyrosine 157 to phenylalanine, lysine 162 to leucine, and tyrosine 168 to phenylalanine, and wherein said modified VP1-capsid protein has a reduced phospholipase A2 enzyme activity as compared to the wild type VP1-capsid protein.
A pharmaceutical composition comprising (a) an adjuvant, and (b) a modified VP1-capsid protein of parvovirus B19, wherein a wild type sequence of the VP1-capsid protein of parvovirus B19 has been modified to contain an amino acid substitution at a position corresponding to tyrosine 157 of SEQ ID NO:
- 1, lysine 162 of SEQ ID NO:
- 1, or tyrosine 168 of SEQ ID NO:
- 1, wherein said substitution is selected from the group consisting of tyrosine 157 to phenylalanine, lysine 162 to leucine, and tyrosine 168 to phenylalanine;
- and wherein said modified VP1-capsid protein has a reduced phospholipase A enzyme activity as compared to the wild type VP1-capsid protein.
Dependencies are inferred from the claim text.